8 Reasons To Eat More Honeydew Melon - Health.com

EntertainmentK-pop A2O Lite members perform at KINTEX in Goyang, Gyeonggi Province, Monday. Newsis By Yonhap A2O Lite, the first girl group produced by former SM Entertainment chief Lee Soo-man, reached No. 1 on Korea's largest music streaming platform shortly after releasing its debut single, before falling to sixth place hours later, data showed Thursday. The group's debut digital single, "Neon," had topped Melon's Top 100 chart by 11 p.m. on Wednesday, 29 hours after its release at 6 p.m. the previous day, according to music industry experts. It is unusual for a rookie group to top the chart within less than two days of a song's release, although it dropped to sixth place the following morning. As of 10 a.m. Thursday, Soyeon's "I'm Gonna Toesa (feat. Kian84)" returned to No. 1. A2O Lite is a nine-member group launched by A2O Entertainment, the company founded by Lee after he left SM Entertainment. Lee simultaneously introduced A2O Lite and 15-member boy group A2O Soul at a media showcase in Goyang, near Seoul, on Monday. He returned to the domestic K-pop market after a three-year non-compete agreement expired earlier this year.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.